Cargando…

Urinary BLACAT1 as a non-invasive biomarker for bladder cancer

BACKGROUND: Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), whi...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sharkawi, Fathia Z., El Sabah, Mahmoud, Atya, Hanaa B., Khaled, Hussein M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147806/
https://www.ncbi.nlm.nih.gov/pubmed/36939965
http://dx.doi.org/10.1007/s11033-023-08370-z
_version_ 1785034869619818496
author El Sharkawi, Fathia Z.
El Sabah, Mahmoud
Atya, Hanaa B.
Khaled, Hussein M.
author_facet El Sharkawi, Fathia Z.
El Sabah, Mahmoud
Atya, Hanaa B.
Khaled, Hussein M.
author_sort El Sharkawi, Fathia Z.
collection PubMed
description BACKGROUND: Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), which retains a feature of rapid progress and metastasis. In addition, only a limited number of biomarkers are available for diagnosing BC compared to other cancers. Hence, finding sensitive and specific biomarkers for predicting the diagnosis and prognosis of patients with BC is critically needed. Therefore, this study aimed to determine the expression and clinical significance of urinary lncRNA BLACAT1 as a non-invasively diagnostic and prognostic biomarker to detect and differentiate BCs stages. METHODS AND RESULTS: The expression levels of urinary BLACAT1 were detected by qRT-PCR assay in seventy (70) BC patients with different TNM grades (T0-T3) and twelve (12) healthy subjects as control. BLACAT1 was downregulated in superficial stages (T0 = 0.09 ± 0.02 and T1 = 0.5 ± 0.1) compared to healthy control. Furthermore, in the invasive stages, its levels started to elevate in the T2 stage (1.2 ± 0. 2), and higher levels were detected in the T3 stage with a mean value of (5.2 ± 0.6). This elevation was positively correlated with disease progression. Therefore, BLACAT1 can differentiate between metastatic and non-metastatic stages of BCs. Furthermore, its predictive values are not like to be influenced by schistosomal infection. CONCLUSIONS: Upregulation of BLACAT1 in invasive stages predicted an unfavorable prognosis for patients with BCs, as it contributes to the migration and metastasis of BCs. Therefore, we can conclude that urinary BLACAT1 may be considered a non-invasive promising metastatic biomarker for BCs.
format Online
Article
Text
id pubmed-10147806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-101478062023-04-30 Urinary BLACAT1 as a non-invasive biomarker for bladder cancer El Sharkawi, Fathia Z. El Sabah, Mahmoud Atya, Hanaa B. Khaled, Hussein M. Mol Biol Rep Original Article BACKGROUND: Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), which retains a feature of rapid progress and metastasis. In addition, only a limited number of biomarkers are available for diagnosing BC compared to other cancers. Hence, finding sensitive and specific biomarkers for predicting the diagnosis and prognosis of patients with BC is critically needed. Therefore, this study aimed to determine the expression and clinical significance of urinary lncRNA BLACAT1 as a non-invasively diagnostic and prognostic biomarker to detect and differentiate BCs stages. METHODS AND RESULTS: The expression levels of urinary BLACAT1 were detected by qRT-PCR assay in seventy (70) BC patients with different TNM grades (T0-T3) and twelve (12) healthy subjects as control. BLACAT1 was downregulated in superficial stages (T0 = 0.09 ± 0.02 and T1 = 0.5 ± 0.1) compared to healthy control. Furthermore, in the invasive stages, its levels started to elevate in the T2 stage (1.2 ± 0. 2), and higher levels were detected in the T3 stage with a mean value of (5.2 ± 0.6). This elevation was positively correlated with disease progression. Therefore, BLACAT1 can differentiate between metastatic and non-metastatic stages of BCs. Furthermore, its predictive values are not like to be influenced by schistosomal infection. CONCLUSIONS: Upregulation of BLACAT1 in invasive stages predicted an unfavorable prognosis for patients with BCs, as it contributes to the migration and metastasis of BCs. Therefore, we can conclude that urinary BLACAT1 may be considered a non-invasive promising metastatic biomarker for BCs. Springer Netherlands 2023-03-20 2023 /pmc/articles/PMC10147806/ /pubmed/36939965 http://dx.doi.org/10.1007/s11033-023-08370-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
El Sharkawi, Fathia Z.
El Sabah, Mahmoud
Atya, Hanaa B.
Khaled, Hussein M.
Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title_full Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title_fullStr Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title_full_unstemmed Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title_short Urinary BLACAT1 as a non-invasive biomarker for bladder cancer
title_sort urinary blacat1 as a non-invasive biomarker for bladder cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147806/
https://www.ncbi.nlm.nih.gov/pubmed/36939965
http://dx.doi.org/10.1007/s11033-023-08370-z
work_keys_str_mv AT elsharkawifathiaz urinaryblacat1asanoninvasivebiomarkerforbladdercancer
AT elsabahmahmoud urinaryblacat1asanoninvasivebiomarkerforbladdercancer
AT atyahanaab urinaryblacat1asanoninvasivebiomarkerforbladdercancer
AT khaledhusseinm urinaryblacat1asanoninvasivebiomarkerforbladdercancer